ABSTRACT: Introduction: Difficulty in modeling congenital contractures (deformities of muscle-tendon unit development that include shortened muscles and lengthened tendons) has limited research of new treatments. Methods: Early immobilization of the ankle in prepuberal mice was used to produce deformities similar to congenital contractures. Stretch treatment, electrostimulation, and local intramuscular injection of a follistatin analog were assessed as therapeutic interventions for these deformities. Results: Ankle immobilization at full plantarflexion and 90 created tendon lengthening and muscle shortening in the tibialis anterior and soleus. Stretch treatment produced minimal evidence for longitudinal muscle growth and electrostimulation provided no additional benefit. Stretch treatment with FST-288 produced greater longitudinal muscle growth and less tendon lengthening, constituting the best treatment response. Discussion: Ankle immobilization recapitulates key morphologic features of congenital contracture, and these features can be mitigated by a combination of stretch and pharmacological approaches that may be useful in patients.
1
These conditions lead to short muscle and long tendon components of the muscle-tendon units (MTU), resulting in impairment of movement. [2] [3] [4] Approximately 1% of all live births show some sort of contracture, 5 which can range from single-joint reduced mobility (such as clubfoot) to severe contractures of several limb joints (such as arthrogryposis multiplex congenita). 1 Despite the broad-ranging impact of contractures, difficulty in modeling these deformities has limited research in this area. The paucity of rodent models of congenital contracture has also slowed the development of alternative or additional therapeutic approaches. Although contracture has been used to describe abnormal limb appearance in some rodent models of central nervous system or neuromuscular disease, these instances are not associated with the tendon lengthening and muscle shortening that we have attempted to model here. The overall goals of this study were the establishment of a model of congenital contracture that was amenable to studies of both mechanism and treatment and the assessment of 3 potential treatment strategies in affecting muscle and tendon growth with this model. To generate the congenital contracture model, we hypothesized that differences in the timing of rodent and human muscle-tendon development were likely responsible for these difficulties and that a model of immobilization-induced muscle shortening would allow the study of contracture therapies. The terminal stages of musculoskeletal maturation in rodents occur in the first few weeks of postnatal life, to the extent that the maturational state of neonatal human muscle most closely corresponds to mouse or rat muscle at 3 weeks of age. 6, 7 Assuming that a lack of movement or mobility at a late but critical developmental stage is sufficient for contracture production, 8, 9 we hypothesized that immobilization early in life could be used to study treatments affecting longitudinal muscle growth. Several classic experiments have demonstrated the potential for immobilization in young rodents to produce shortened muscles and lengthened tendons. [9] [10] [11] [12] [13] [14] More recent studies have used immobilization to study the later onset contractures seen in cerebral palsy and other disorders, 15, 16 but treatment and longitudinal muscle growth were not key foci of these systems. This study expands on that work to develop an immobilization-based model that evaluates longitudinal muscle growth as a key endpoint for the evaluation of treatments. The development of a reproducible model of immobilization-induced muscle shortening provides a means for studying contractures in a genetically normal (CD-1) mouse background, which is highly desirable because the majority of patients with contracture do not suffer from genetic disease. 17 Treatment of contractures is focused on the specific symptoms experienced by each individual and may include physical therapy, removable splints, exercise, and/or surgery. Therapy of severely affected patients is generally long term, with the potential to achieve some level of ambulation in many patients. 18, 19 Progressive resistance exercise has demonstrated the potential to increase strength in the context of contractures associated with cerebral palsy (which are likely distinct from congenital contractures), which suggests a possible role for muscle growth in contracture treatment. 20 Current therapeutic strategies for contracture are generally focused on restoring flexibility but have not been designed to improve strength. 21 Therapies that promote longitudinal muscle growth could dramatically improve therapeutic outcomes. A number of genetic and pharmacological studies have shown that inhibiting myostatin/activin receptor type IIB (ActRIIB) signaling can produce marked myofiber hypertrophy to increase muscle mass and strength. 22 Follistatin, a potent antagonist of myostatin/ActRIIB signaling, has been found to increase muscle mass locally after intramuscular injection and is capable of producing axial myofiber growth. [23] [24] [25] However, the capacity of follistatin to promote longitudinal muscle growth is unclear. We hypothesize that therapy for immobilization-induced muscle shortening is improved by combining physical and pharmacological therapies.
MATERIALS AND METHODS
Live Animal Studies. All studies were performed with approval from the institutional animal care and use committee at The Medical College of Wisconsin. Both male and female mice were used on the basis of their equivalency in pilot experiments. CD-1 albino mice (Charles River Laboratories, Portage, Michigan) without genetic abnormalities were used for all experiments. During the period of immobilizationinduced muscle shortening generation and treatment, mice were monitored daily through visual inspection and measurement of body weight.
Ankle
Immobilization to Create MTU Abnormalities. The overall experimental design is illustrated in Figure 1 . Proof-of-concept studies of ankle immobilization were performed in the plantarflexed position (illustrated in Supp. Info. Fig. 1 ) without inversion or eversion of the foot. Additional experiments were performed to assess MTU development after immobilization at a 90 angle (tibialplantar angle, without inversion or eversion of the foot) to allow stretch in either the plantarflexed or dorsiflexed positions. Position and condition of the splinted ankle were monitored daily, and additional bands of tape were added to maintain immobilization with limb growth. Splints were entirely removed at 3 weeks of age, and animals were evaluated for contracture formation. Some cohorts of mice were then either exposed to therapeutic interventions for an additional 2 weeks or assessed for the persistence of contractures for an additional 8 weeks.
Ankle Splinting to Produce Progressive Stretch. To assess the impact of progressive stretch on MTU growth in the tibialis anterior (TA) muscle, mice with immobilizationinduced muscle shortening produced at 90 had their ankles resplinted in progressively plantarflexed positions over a Assessment of Combined Stretch Treatment Plus Electrostimulation Treatment. To determine whether increased isometric contractile activity would promote longitudinal muscle growth beyond what is seen with stretch treatment alone, awake mice with immobilization-induced muscle shortening produced at 90 underwent leg electrostimulation for 30 min/day with concurrent progressive stretch in 3 stages over a 2-week period (from 3 to 5 weeks of age). Contraction of leg muscles was evoked by transcutaneous stimulation to the fibular and tibial nerves with a loop electrode (cathode) encircling the leg below the fibular head and a patch electrode (anode) against the shaved lower back. The procedure was developed in 13-15-day-old awake mice, and maximum current intensity was defined as the level that produced strong TA and gastrocnemius isometric contractions without activating thigh or tail muscles or causing vocalization and startle movements. At maximum, the contracting muscles of the splinted limb were palpably hard, and the leg, ankle, and foot stiffened visibly from the opposing tensions developed by cocontraction of the dorsiflexor and plantarflexor muscles. Electrode (carbonized rubber) conductance was facilitated by using Spectra 360 electrode gel (Parker Laboratories, Fairfield, New Jersey). The pattern and waveform of stimulation used were based on those employed in humans to build muscle strength with minimal fatgue 26 and were well tolerated 30 min/day by the awake mice constrained under soft nylon netting. Electrode impedance averaged 34 ± 4 kΩ. The stimuli were generated by a Grass S88 stimulator (Grass Instruments, West Warwick, Rhode Island) producing square pulses of 11-28 V (16.1 ± 2.1) at 50 HZ that were converted to biphasic pulses (400-μs duration) via an SIU 5 isolator (Grass Instruments, West Warwick, Rhode Island). The stimulation, delivered in a duty cycle of 1-s-on 3-s-off trains, was repeated continuously for 30 min. Maximum contractions were elicited by stimulating currents averaging 13.2 ± 1.7 mA (range, 8.9-21.8).
Assessment of Stretch Treatment Plus FST-288
Injection. We evaluated longitudinal muscle growth using FST-288, a locally distributing follistatin analog that was not expected to have therapeutic effects outside the injected leg. 23 Mice with immobilization-induced muscle shortening produced at 90 underwent intramuscular injections with FST-288 concurrently with progressive stretch over a 2-week period (from 3 to 5 weeks of age). Stretch was performed in 5 stages to allow injections and splint changes to be performed at the same time. Mice received semiweekly intramuscular 20-30 μl injections of drug or vehicle into the lateral compartment (fibularis muscles). Additional control groups in this study included mice without immobilization-induced muscle shortening or stretch treatment but with intramuscular injection of FST-288 at the same location and mice with immobilization-induced muscle shortening and 5-stage stretch treatment but with injection of vehicle (Tris-buffered saline) instead of FST-288.
Bone, Muscle, and Tendon Measurements. Depending on the experiment involved, animals were humanely killed for anatomical evaluation and tissue collection at 3 weeks (proof-of-concept experiments), 5 weeks (treatment experiments), or 11 weeks (persistence experiments) of age. After animals were killed, hind limbs were removed above the knee and fixed in phosphate-buffered saline containing 4% paraformaldehyde (pH 7.2) and stored at 4 C. The tibiae and leg muscles with complete tendons were removed from the treated and control sides. Lengths were measured with the aid of dissecting microscope magnification and a ruler graduated in 0.5-mm units.
The tendon arising distally in the TA was cut at the insertion on the first metatarsal. Proximally, TA muscles were freed from their origin in the tibial periosteum to preserve full length myofibers. Muscle (belly) length was taken from the most proximal fiber origin to the farthest distal fiber attachment to the tendon. Extensor digitorum longus (EDL) tendons were dissected at the single proximal tendon originating from the lateral epicondyle of the femur and the distal tendon attached to the middle (third) digit. The soleus tendons were cut at the calcaneal insertion and the lateral tibia below the knee joint. Plantaris tendons were cut at the lateral femoral epicondyle and the calcaneal insertion. When calculating the percentage of total tendon length to muscle belly length in the EDL, soleus and plantaris, the lengths of the proximal and distal tendons were summed.
Determination of Sarcomere Number. Experiments evaluating the effects of stretch treatment, electrostimulation, and FST-288 injection also used the number of sarcomeres in series to quantify longitudinal muscle growth. After measurement of muscle belly and tendon lengths with a dissecting microscope, the TA muscles were further dissected. The total length of single fibers was the distance between the attachment on distal tendon to the proximal origin on the periosteum. A 1-2-mm mid-fiber segment was then cut from the myofibers whose length had been measured. The segment was mounted in Fluoromount aqueous medium (Millipore Sigma, St Louis, Missouri) on a glass slide and coverslipped. The cross striations of individual myofibers were brought into focus and photographed with a Spot RT3 digital camera (SPOT Imaging; Diagnostic Instruments, Sterling Heights, Michigan) attached to an E600 light microscope (Nikon Tokyo, Japan) with the × 40 objective and the substage condenser closed down to enhance sarcomere cross striations. The images were opened in MetaMorph Imaging software 7.8 (Diagnostic Instruments). The distance morphometry program was employed to measure the distance covered by 10 sarcomeres in series in 30 different myofibers per muscle. The total number of sarcomeres per myofiber was calculated by dividing the measured myofiber length (prior to dissection) by the average length of a single sarcomere for the same myofibers.
Statistical Analysis. Data were first evaluated by the Kolmogorov-Smirnov test for normality and Barlett's test for equal variances. Student's t test or one-way ANOVA with post hoc Tukey-Kramer testing was used for those that passed. For those that failed and that did not achieve normality with Box Cox transformation (sarcomere number, tendon length, and tendon %/MTU), nonparametric testing (Mann-Whitney or KruskalWallis with post hoc Dunn's multiple-comparison test) was used. Statistics were conducted in Prism 7 (GraphPad Software, La Jolla, California), and significance was accepted at P < 0.05. See figure legends for specific statistical analysis of each data set.
When comparing within a group, the splinted side was compared with the contralateral nonsplinted limb. The values for each mouse were normalized by the ratio of the left (L) splinted to (R) right nonsplinted side. Group data compared in this manner included L/R sarcomere number, L/R tendon length, sarcomere number/tendon length, L/R percentage tendon length/ MTU, and L/R sarcomere number/tendon length.
RESULTS
Animal Condition Assessments. Splinted mice were generally very tolerant of the ankle immobilization procedure, and no animals were removed from the study due to distress. The ratio percentage of immobilized to nonimmobilized tibia length across all groups averaged 99.6% ± 0.9%, which is consistent with preservation of tibial growth. Overall length of the MTU was also assessed in all experiments, and data are reported in figure infographics. Overall, changes in total MTU length (either lengthening or shortening) were within 5% of normal/nonsplinted values. Contralateral controls were not different from nontreated controls conducted in parallel.
Ankle Immobilization in the Plantarflexed State. Ankle immobilization in the fully plantarflexed splinting position produced a demonstrable deformity of the ankle (Fig. 2) including shorter muscles and longer tendons (soleus splinted 12.1 ± 0.1 mm, unsplinted 12.6 ± 0.3 mm; TA splinted 16.0 ± 0.4 mm, unsplinted 16.6 ± 0.4 mm), which can be expressed as the percentage of the total MTU that corresponds to the TA tendon (Fig. 3) . Measurement of the MTUs of the TA, soleus, plantaris, and EDL muscles at 3 weeks of age revealed longer tendons and shorter muscles in the soleus and TA muscles that cross only the ankle (soleus tendon/total length ratio increased 9% ± 2%, P = 0.002), and TA tendon/total length increased 17% ± 2% (P = 0.002) relative to the unsplinted side (Fig. 3) . The plantaris and EDL muscles that crossed both the ankle and nonimmobilized knee joints did not display tendon lengthening (plantaris tendon/ total length increased 1% ± 3% and EDL tendon/ total length increased 0% ± 1% after immobilization). Light microscopic comparison of epoxy-embedded normal and immobilized muscles revealed intact sarcomeres and myofibrils without evidence of endomysial fibrosis or muscle fiber degeneration (Fig. 2D) . To evaluate the potential for contractures to persist long term, a subset of animals with ankle immobilization during weeks 1-3 of life were then followed without further immobilization or intervention until 11 weeks of age. Despite the lack of imposed ankle immobilization between 3-11 weeks of age, the deformities of the ankle and the tendon lengthening consistent with contracture persisted in the TA (TA tendon/total length greater by 8% ± 2%, P = 0.016) on the side that had been immobilized (Fig. 3) . A summary infographic of these data is shown in Figure 3B . showed significant tendon lengthening when evaluated at 5 weeks of age, without further immobilization or other interventions (TA tendon/total length increased 13% ± 2% compared with nonimmobilized TA, P = 0.012; Fig. 4 ). Decreased longitudinal muscle growth was further demonstrated by a decrease in TA serial sarcomere number (30% ± 2% decrease in immobilized limbs compared with nonimmobilized limbs, P = 0.026) and the ratio of sarcomere number/ tendon length (decreased by 48% ± 3% when comparing the TAs of immobilized vs. nonimmobilized limbs, P = 0.0079) in animals with immobilization and no treatment compared with their nonimmobilized limbs. , 162 , and 180 ) was evaluated and elicited essentially identical results (Fig. 4 and 5) . Measurements of sarcomere numbers and sarcomere number/tendon length calculations were suggestive of a modest benefit to longitudinal muscle growth as a result of stretch treatment. Sarcomere number decreased 17% ± 4% (P = 0.026) in TAs from immobilized limbs compared with nonimmobilized limbs after stretch treatment (Fig. 4) . Sarcomere numbers were not significantly different from the 30% ± 2% decrease seen in immobilized TAs without treatment. When viewed as the ratio of sarcomere number/tendon length, TAs from immobilized limbs showed decrease of 38% ± 4% (P = 0.0022; Fig. 4 ) compared with nonimmobilized limbs. These values are consistent with a modest benefit compared with the 48% ± 3% decrease observed in untreated animals with immobilization-induced muscle shortening (P = 0.0079)
Effect of Electrostimulation and Stretch on ImmobilizationInduced Muscle Shortening at 90
. Evaluation of TA muscle and tendon lengths after 2 weeks of stretch + electrostimulation revealed that there was no additional benefit to tendon length (increased by 13% ± 1% with stretch + electrostimulation compared with 13% ± 2% with no treatment and 10% ± 1% with stretch alone). Similarly, decreases in sarcomere number (23% ± 2%), and sarcomere number/tendon length (decreased by 42% ± 2%) was not indicative of longitudinal muscle growth beyond that observed with stretch treatment alone (Fig. 4) . . In mice without ankle immobilization and lacking immobilizationinduced muscle shortening, FST-288 exposure did not alter longitudinal muscle growth, as indicated by similar TA tendon/total lengths (within1% ± 1%), sarcomere numbers (within 3% ± 4%), and sarcomere number/tendon length (within 7% ± 5%) on injected compared with noninjected sides (Fig. 5) . Control mice receiving 5 stages of stretch with vehicle injections showed similar degrees of tendon lengthening compared with our earlier stretch treatment studies (TA tendon/total MTU lengths greater by 17% ± 1%, P = 0.005); sarcomere numbers were lower by 30% ± 3% (P = 0.0022), and sarcomere number/tendon length was lower by 49% ± 3% (P = 0.0022; Fig. 5 ). Treatment of animals with immobilizationinduced muscle shortening with FST-288 in addition to stretch treatment produced a significant improvement by producing less of an increase in tendon/total MTU length (increased by 10% ± 1% compared with nonimmobilized TA) while producing less of a decrease in sarcomere number (decreased by 18% ± 1% compared with nonimmobilized TA, P = 0.0331). Sarcomere number/tendon length was also dramatically improved (decreased by 30% ± 2% compared with nonimmobilized TA, P = 0.0073; Fig. 5 ). When comparing stretch treatment alone to stretch + FST288, there was significant improvement in the ratio of unsplinted to splinted limbs with respect to sarcomere number/ tendon length values (P < 0.01). A summary of these results can also be found in Supporting Information Table 1 . , and sarcomere number/tendon length (bottom) measurements for the unsplinted (gray) and immobilized (colored) limbs in each group. *P < 0.05, **P < 0.01, ***P < 0.001; tendon length and sarcomere number Mann-Whitney, sarcomere number/tendon length ANOVA. MTU, muscle-tendon unit.
DISCUSSION
The results of our study demonstrate the potential for ankle immobilization as a model for the study of longitudinal muscle growth, particularly in the study of potentially useful therapeutic approaches. As suspected, the ability to induce muscle shortening and tendon lengthening was highly dependent on whether the MTU was capable of even limited movement. Although immobilization at the full ankle plantarflexion position produced tendon lengthening and muscle shortening in the soleus and TA muscles (which cross only the ankle joint), there was no evidence of MTU abnormality in the plantaris and EDL muscles (which cross both the ankle and knee joints and were thus not entirely immobilized by the ankle splinting).
The primary discovery from our study was that the intervention with the greatest impact on longitudinal muscle growth in contractures was a combination of stretch treatment and FST-288 injection. Stretch treatment alone had little impact on promoting longitudinal muscle growth in the TA muscle of developing mice. Stretch treatment alone may, however, be a more useful therapeutic option at later ages. The use of stretch therapy in the management of children with muscle contractures is based on its established effects in the adult population, in which the stretch stimulus does not lead to tendon lengthening. 13, 27 In preadolescent experimental animals, however, stretch can produce tendon growth that outpaces the longitudinal growth of the muscle to generate a poorly functional MTU. 8, 10, 13 Fortunately, stretch treatment did not negatively impact MTU development in this study. However, our findings also indicate that stretch alone may not have the positive impact on longitudinal muscle growth that has been described in adults. Electrostimulation treatment used here did not alter the , and sarcomere number/tendon length (bottom) measurements for the unsplinted (gray) and immobilized (colored) limbs in each group. *P < 0.05, **P < 0.01, ***P < 0.001; tendon length and sarcomere number Mann-Whitney, sarcomere number/tendon length ANOVA. MTU, muscle-tendon unit.
growth of the MTU. Although it is possible that longer or more frequent/involved electrostimulation treatment could be of benefit, the protocol used here was designed with clinical feasibility in mind, and the ability to translate such protocols to the clinical setting may be challenging.
Progressive stretch with serial casting is similar to the Ponseti casting strategy currently used for the treatment of contractures. Ponseti casting involves a series of castings, Achilles tenotomy, and foot bracing to produce correction and avoid more extensive correction. 28 However, it is likely that this treatment can be improved with the integration of strategies to promote longitudinal muscle growth. The current duration of postcasting splinting is highly variable (from 2 to 5 years) because of uncertainty over the duration required to avoid reversion of the structural abnormalities. Additional study in this area may allow improvements in cast design and a clearer understanding of the required duration of casting treatments.
The most promising finding here is the evidence of additional benefit to longitudinal muscle growth when stretch treatment is combined with FST-288. A number of genetic and pharmacological studies have shown that inhibiting myostatin/ActRIIB signaling can produce marked myofiber hypertrophy to increase muscle mass and strength. 22 In our prior work, we have demonstrated the capacity of ActRIIBmFc (Acceleron Pharma), a soluble activin type IIB receptor, to increase muscle size and strength in healthy mice. 29 In treating immobilization-induced muscle shortening, however, local delivery and efficacy of a therapeutic agent was more desirable, and FST-288 better fit that profile. In this study, the effects of follistatin on MTU growth were assessed in immobilization-induced muscle shortening also treated with stretch treatment because we believed that stretch would be required to stimulate longitudinal muscle growth. FST-288 plus stretch treatment promoted longitudinal muscle growth with decreased tendon lengthening over the 2-week treatment period. The promotion of longitudinal muscle growth was mild but significant, and future work will focus on determining the functional impact of longitudinal muscle growth and whether treatment responses can be improved by extending the period of treatment. The pilot experiments reported here, however, offer interesting new directions in researching innovative therapeutic approaches for contractures.
Animal casting experiments were performed in collaboration with the Neuroscience Research Center's Behavioral Core Facility at the Medical College of Wisconsin, which is funded by the Research and Education Initiative Fund, a component of the Advancing a Healthier Wisconsin Endowment at the Medical College of Wisconsin.
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